Jump to content
  • Sign Up
0
Scott Adams

ImmusanT gets $20M Series A shot for celiac vaccine - Mass High Tech

Rate this topic

Recommended Posts

6.jpg

Mass High Tech

ImmusanT gets $20M Series A shot for celiac vaccine

Mass High Tech

By Rodney Brown Cambridge-based biotechnology company ImmusanT Inc. has raised a Series A round of funding, bringing in $20 million from Vatera Healthcare Partners LLC of New York to move forward its treatment for celiac disease. ...

ImmusanT Raises $20 Million in Series A Financing to Advance Immunotherapeutic ... PR Newswire (press release)

ImmusanT, Developing Celiac Disease Treatments, Closes $20M Series A Xconomy

Cambridge, MA startup snags $20M for therapeutic vaccine program FierceBiotech

Fortune (blog)

all 16 news articles »

View the full article

Share this post


Link to post
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now
0

×